Stocktoria
Tonix Pharmaceuticals Holding Corp. TNXP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-03-29
Tonix Pharmaceuticals Holding Corp. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -959.1% | -1354.3% | -1523.9% | — | — |
| Net margin | -946.2% | -1288.3% | -1501.8% | — | — |
| FCF margin | -787.5% | -604.8% | -1414.8% | — | — |
| Return on assets | -44.7% | -79.8% | -75.5% | -48.8% | -38.3% |
| Return on equity | -50.6% | -93.2% | -110.6% | -53.2% | -42.2% |
| Debt / equity | — | 0.06× | 0.10× | — | — |
| Current ratio | 7.42 | 6.50 | 2.53 | 7.19 | 8.71 |
| Revenue growth | 29.8% | 29.9% | — | — | — |
Source: SEC EDGAR filings · CIK 0001430306 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.